Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02319772 | A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430 | PHASE1 | COMPLETED | 94 | — | — | Dec 1, 2014 | Apr 1, 2016 | Jul 7, 2016 | 1 | United Kingdom |
Evaluation of the incidence and severity of adverse events, laboratory abnormalities, ECG findings, vital sign changes, injection site and physical examination findings
| Arm | Type | Description |
|---|---|---|
| BCX4430 | EXPERIMENTAL | BCX4430 administered as an IM injection |
| Placebo | PLACEBO_COMPARATOR | Matched placebo administered as an IM injection |
| Name | Type | Description |
|---|---|---|
| BCX4430 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: 1. Weight ≥ 50 kg (110 lbs) and ≤ 100 kg (220 lbs) 2. Body mass index (BMI) of 19-32 kg/m2 3. Willing to abstain from alcohol consumption for a period of 2 days prior to and during the study 4. Sexually active women of child bearing potential and sexually active men must utilize...